Date Time
Update on DARE-19 Phase III trial for Farxiga in COVID-19
AstraZeneca and Saint Luke’s Mid America Heart Institute today announced high-level results of the primary analysis from the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin) to treat patients hospitalised with COVID-19 who are at risk of developing serious complications.
The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death), at 30 days.
DARE-19 was the first Phase III trial to evaluate the safety and efficacy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients hospitalised with COVID-19 who also have risk factors for developing serious complications, including hypertension (HTN), type-2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) or chronic
American Heart Association
Research Highlights:
The ability of HDL particles (commonly known as “good” cholesterol) to reduce inflammation in the cells that line blood vessels may help predict who is more likely to develop a heart attack or other serious heart-related event.
Gauging the anti-inflammatory capacity of HDL cholesterol may one day improve standard heart disease risk assessment.
The results may encourage greater attention to the function of HDL particles in addition to quantity of cholesterol within HDL in determining how to assess and reduce heart disease risk.
DALLAS, April 12, 2021 Testing how well “good” cholesterol particles reduce inflammation may help predict who is at heightened risk to develop cardiovascular disease caused by narrowed arteries, according to research published today in the American Heart Association’s flagship journal
By Lydia Davis
Emerging evidence shows that variability in your A1C level may put you at a higher risk of stroke and heart disease.
A recent study revealed that variability in an individual’s A1C levels could be associated with their risk for developing diabetes-related complications, such as heart disease.
The study looked at the electronic health record data of almost 30,000 people with type 2 diabetes from 2013 to 2018 in southeast Louisiana. It included people who had at least four A1C measurements within two years of their diabetes diagnosis and no heart-related complications within that two-year period or the year before diagnosis. The sample’s demographics were 59% white and 41% African American.
Top Story
April 2, 2021
ISLAMABAD: The Supreme Court (SC) on Thursday issued notices to heads of the National and Provincial Health Commissions in substandard cardiac stents case. A three-member SC bench, comprising Chief Justice Gulzar Ahmed, Justice Ijazul Ahsan and Justice Sayed Mazahar Ali Akbar Naqvi, heard the case pertaining to imbedding substandard cardiac stents. The court also issued notices to all four provincial advocate generals. The court observed that cardiovascular issues were left to inexperienced specialists.
The court rejected the National Accountability Bureau (NAB) request to make NAB member of pricing committee.
At the outset of hearing, the court observed that substandard cardiac stents were being used across the country. The court sought implementation report on National Interventional Cardiology Board (NICB) recommendations.
Top Story
April 2, 2021
ISLAMABAD: The Supreme Court (SC) on Thursday issued notices to heads of the national and provincial health commissions in substandard cardiac stents case.
A three-member SC bench, comprising Chief Justice Gulzar Ahmed, Justice Ijazul Ahsan and Justice Sayed Mazahar Ali Akbar Naqvi, heard the case pertaining to imbedding substandard cardiac stents. The court also issued notices to all four provincial advocate generals.
The court observed that cardiovascular issues were left to inexperienced specialists.
The court rejected the National Accountability Bureau (NAB) request to make NAB member of pricing committee.
At the outset of hearing, the court observed that substandard cardiac stents were being used across the country. The court sought implementation report on National Interventional Cardiology Board (NICB) recommendations.